Fate Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Good morning, everybody. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts here at Barclays. And I think -- I just want to thank everybody for joining us -- for taking time out of their day. If you have questions for me, kind of know-how to reach me, [email protected], or you can ping me on Bloomberg.
And it gives me great pleasure today to introduce the team from Fate Therapeutics. So we've got Scott Wolchko and Ed Dulac, CFO. And so just as an introductory question I've asked, I think I asked you this question multiple times. And many of my questions -- many have might come to this multiple times as well. Just the point -- the differentiation of Fate in the oncology space kind of -- what do you kind of view as your core competencies? And then we'll kind of dive into questions.
Sure. So cell-based cancer immunotherapy company.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |